

*Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.*

## **FOR IMMEDIATE RELEASE, August 14, 2001**

### **Immunex Announces Next Step to Boost ENBREL® (etanercept) Production**

BioNext Project<sup>a</sup> will make Rhode Island Manufacturing Center The Largest Site for Cell Culture Manufacturing Capacity in the World

\*\*\*

SEATTLE - Immunex Corporation [Nasdaq: IMNX] today announced that it plans to initiate construction of a new manufacturing plant in West Greenwich, Rhode Island, pending approval of appropriate permits. Once the new building is completed, the site will comprise the largest cell culture manufacturing center in the world.

"We expect the BioNext Project will bring the fourth facility producing ENBREL online in 2005 and it is a key element of the execution of our strategic plan designed to satisfy growing demand in existing and emerging markets," said Peggy Phillips, executive vice president and chief operating officer at Immunex. "The construction of this new plant will make Immunex one of the world's leaders in biotechnology manufacturing, a key goal given the success of our marketed products and our need for manufacturing pipeline products in the future. We appreciate the welcome we have received from the State of Rhode Island and the West Greenwich township."

The BioNext Project involves an investment of approximately \$500 million to construct the new facility, which will house the largest bioreactors ever used in the industry. Conceptual design of the facility is complete and the company anticipates beginning construction in the fourth quarter of this year, pending receipt of appropriate zoning and environmental permits. The project is expected to be licensed by regulatory authorities in 2005.

"The BioNext Project demonstrates our commitment to continuous process improvements and capital investments that increase yields and production capacity - these are the cornerstones of successful biotechnology manufacturing operations," said Efi Cohen Arazi, senior vice president of supply operations at Immunex.

The BioNext Project will add to three other facilities that are producing or will produce ENBREL. Currently, Immunex is working with Wyeth-Ayerst Pharmaceuticals, a division of American Home Products Corporation (NYSE: AHP) to retrofit an existing manufacturing facility on the West Greenwich, RI site. AHP purchased the facility in 1999 to help meet the growing market demand for ENBREL. AHP has agreed to sell the site to Immunex. AHP also is building a facility in Grange Castle, Ireland that will manufacture ENBREL. ENBREL is currently produced by a contract manufacturer in Germany.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

*NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and*

*Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at [www.immunex.com](http://www.immunex.com).*